Are PAR collecting data on the reduction in requirements of other forms of meds? If patients are on prescribed opiods or NSAIDS and no longer requiring them that would be a healthy saving to the health system. They really should be collecting this sort of data in the phase 3 trials. Has there been any talk of getting a health economist on board? Be interesting to see a cost benefit analysis in conjunction with the QoL/pain questionnaires and MRI results.
PPS completed 12 injection course, page-20
-
- There are more pages in this discussion • 198 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
-0.010(3.85%) |
Mkt cap ! $87.44M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 24.5¢ | $261.8K | 1.036M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 224663 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 19873 | 2 |
View Market Depth
| Last trade - 15.34pm 31/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |